These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16869814)

  • 1. Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy.
    van Zanten AR; Oudijk M; Nohlmans-Paulssen MK; van der Meer YG; Girbes AR; Polderman KH
    Br J Clin Pharmacol; 2007 Jan; 63(1):100-9. PubMed ID: 16869814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease.
    Conte JE; Golden JA; McIver M; Little E; Zurlinden E
    Int J Antimicrob Agents; 2007 Nov; 30(5):422-7. PubMed ID: 17716873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.
    Rafati MR; Rouini MR; Mojtahedzadeh M; Najafi A; Tavakoli H; Gholami K; Fazeli MR
    Int J Antimicrob Agents; 2006 Aug; 28(2):122-7. PubMed ID: 16815689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of continuous infusion with intermittent bolus administration of cefotaxime on blood and cavity fluid drug concentrations in neonatal foals.
    Hewson J; Johnson R; Arroyo LG; Diaz-Mendez A; Ruiz-López JA; Gu Y; del Castillo JR
    J Vet Pharmacol Ther; 2013 Feb; 36(1):68-77. PubMed ID: 22489635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration.
    Laterre PF; Wittebole X; Van de Velde S; Muller AE; Mouton JW; Carryn S; Tulkens PM; Dugernier T
    J Antimicrob Chemother; 2015 Mar; 70(3):891-8. PubMed ID: 25433006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlation between pulmonary pharmacokinetics and pharmacodynamics support the hypothesis of the usefulness of ceftazidime at a single 1g daily dose in the treatment of bacterial exacerbation of chronic obstructive bronchopneumonia with moderate functional damage].
    Cazzola M; Noschese P; Vinciguerra A; Di Perna F; Califano C; Berra A
    Minerva Med; 1998; 89(1-2):15-22. PubMed ID: 9561021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of lower respiratory tract infections including pneumonia. Comparative study with i.vl cefotaxime/oral cefixime versus parenteral cefotaxime].
    Vogel F
    Fortschr Med; 1994 Oct; 112(28):395-8. PubMed ID: 7988978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ceftriaxone in the therapy of infections of the lower respiratory tract: comparison with cefotaxime].
    Lanni N; Scaglione B
    Minerva Med; 1986 Mar; 77(9-10):317-9. PubMed ID: 3485265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefodizime once daily in the treatment of lower respiratory tract infections.
    Piovano CF; Palombini BC; Dagrosa EE; Mendoza F; Facco EB
    Arzneimittelforschung; 1997 May; 47(5):674-7. PubMed ID: 9205786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences between ceftriaxone and cefotaxime: microbiological inconsistencies.
    Gums JG; Boatwright DW; Camblin M; Halstead DC; Jones ME; Sanderson R
    Ann Pharmacother; 2008 Jan; 42(1):71-9. PubMed ID: 18094350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.
    Sakka SG; Glauner AK; Bulitta JB; Kinzig-Schippers M; Pfister W; Drusano GL; Sörgel F
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3304-10. PubMed ID: 17620371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.
    van Zanten AR; Polderman KH; van Geijlswijk IM; van der Meer GY; Schouten MA; Girbes AR
    J Crit Care; 2008 Sep; 23(3):422-30. PubMed ID: 18725050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic resistance in sputum isolates of Streptococcus pneumoniae in chronic obstructive pulmonary disease is related to antibiotic exposure.
    Desai H; Richter S; Doern G; Heilmann K; Dohrn C; Johnson A; Brauer A; Murphy T; Sethi S
    COPD; 2010 Oct; 7(5):337-44. PubMed ID: 20854048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of ceftizoxime administered twice daily in hospitalized patients with respiratory tract infections.
    Lentnek A; Wikler M; McDevitt J; Sohn C
    Clin Ther; 1984; 7(1):33-9. PubMed ID: 6097357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibacterial therapy of acute infectious exacerbation of chronic obstructive pulmonary disease.
    Chelidze K; Jgarkava M
    Georgian Med News; 2008 Jun; (159):27-30. PubMed ID: 18633147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of free ertapenem in critically ill septic patients: intermittent versus continuous infusion.
    Breilh D; Fleureau C; Gordien JB; Joanes-Boyau O; Texier-Maugein J; Rapaport S; Boselli E; Janvier G; Saux MC
    Minerva Anestesiol; 2011 Nov; 77(11):1058-62. PubMed ID: 21597443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.